# EDGAR Filing Document

**Accession Number:** 0001673772
**File Stem:** 0001193125-23-070131
**Filing Date:** 2023-3
**Character Count:** 19550
**Document Hash:** 5fae2b08788f19832cb4f58e66d245dc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-070131.hdr.sgml**: 20230314

**ACCESSION NUMBER**: 0001193125-23-070131

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230314

**DATE AS OF CHANGE**: 20230314

**EFFECTIVENESS DATE**: 20230314

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RAPT Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001673772
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 473313701
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270523
- **FILM NUMBER:** 23730726

**BUSINESS ADDRESS:**
- **STREET 1:** 561 ECCLES AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 489-9000

**MAIL ADDRESS:**
- **STREET 1:** 561 ECCLES AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FLX Bio, Inc.
- **DATE OF NAME CHANGE:** 20160504

**As filed with the Securities and Exchange Commission on March 14, 2023** 

**Registration No. 333-** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

------

## RAPT Therapeutics, Inc.
**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **47-3313701** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **561 Eccles Avenue**<br> **South San Francisco, California** | **94080** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

------

**2019 Equity Incentive Plan** 

**(Full titles of the plans)** 

------

**Brian Wong** 

**President and Chief Executive Officer** 

**RAPT Therapeutics, Inc.** 

**561 Eccles Avenue** 

**South San Francisco, California 94080** 

**(Name and address of agent for service)** 

**(650) 489-9000** 

**(Telephone number, including area code, of agent for service)** 

------

***Copies to:***

**Michael Tenta** 

**Courtney M.W. Tygesson** 

**Cooley LLP** 

**3175 Hanover Street** 

**Pal Alto, CA 94304** 

**(650) 843-5000** 

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

RAPT Therapeutics, Inc. (the "***Registrant***") is filing this Registration Statement on Form S-8 for the purpose of registering an additional 1,370,173 shares of common stock, par value $0.0001 per share (the "***Common Stock***"), issuable pursuant to the Registrant's 2019 Equity Incentive Plan (the "***2019 Plan***").

Pursuant to General Instruction E of Form S-8, the contents of the Registrant's Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the "***Commission***") on November 1, 2019 ([File No. 333-234448](http://www.sec.gov/Archives/edgar/data/1673772/000119312519282006/d828567ds8.htm)), March 30, 2020 ([File No. 333-237487](http://www.sec.gov/Archives/edgar/data/1673772/000119312520091108/d901936ds8.htm)), March 11, 2021 ([File No. 333-254127](http://www.sec.gov/Archives/edgar/data/1673772/000119312521077141/d133614ds8.htm)) and March 10, 2022 ([File No. 333-263426](http://www.sec.gov/Archives/edgar/data/1673772/000119312522072000/d121293ds8.htm)) are hereby incorporated in this Registration Statement by reference to the extent not replaced hereby.

**PART II** 

---

| | |
|:---|:---|
| **ITEM 3.** | **INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE**  |

---

The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

(a) The Registrant's Annual Report on Form 10-K (File No. 001-38997) for the fiscal year ended December 31, 2022, filed with the Commission on [March 14, 2023](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1673772/000095017023007710/rapt-20221231.htm).

(b) The Registrant's Current Reports on Form 8-K (File No. 001-38997) (other than information furnished rather than filed) filed with the Commission on [January 9, 2023](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001673772/000119312523004174/d434788d8k.htm) and [March 14, 2023](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1673772/000095017023007712/rapt-20230314.htm).

(c) The description of the Registrant's Common Stock which is contained in a registration statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1673772/000119312519199060/d779692d8a12b.htm) on July 22, 2019 (File No. 001-38997) under the Securities Exchange Act of 1934, as amended (the" ***Exchange Act***"), including any amendment or report filed for the purpose of updating such description, including [Exhibit 4.2](http://www.sec.gov/Archives/edgar/data/1673772/000156459020014162/rapt-ex42_1343.htm) to the Registrant's Annual Report on Form 10-K (File No. 001-38997) for the fiscal year ended December 31, 2019, filed with the SEC on March 30, 2020.

(d) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

---

| | |
|:---|:---|
| **ITEM 8.** | **EXHIBITS**  |

---

The exhibits to this Registration Statement are listed below.

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Exhibit**<br> **Number** | **Exhibit Description** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Filed<br>Herewith** |
| **Exhibit**<br> **Number** | **Exhibit Description** | **Form** | **File No.** | **Exhibit<br>No.** | **Filed On** | **Filed<br>Herewith** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Amended and Restated Certificate of Incorporation](http://www.sec.gov/Archives/edgar/data/1673772/000119312519283350/d825897dex31.htm) | 8-K | 001-38997 | 3.1 | 11/04/19 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Amended and Restated Bylaws](http://www.sec.gov/Archives/edgar/data/1673772/000119312519283350/d825897dex32.htm) | 8-K | 001-38997 | 3.2 | 11/04/19 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 | [Form of Common Stock Certificate](http://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex41.htm) | S-1 | 333-232572 | 4.1 | 07/22/19 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 | [RAPT Therapeutics, Inc. 2019 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex104.htm) | S-1 | 333-232572 | 10.4 | 07/22/19 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 | [Form of Restricted Stock Unit Award Agreement and Grant Notice for RAPT Therapeutics, Inc. 2019 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex106.htm) | S-1 | 333-232572 | 10.6 | 07/22/19 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 | [Form of Stock Option Agreement and Grant Notice for RAPT Therapeutics, Inc. 2019 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex105.htm) | S-1 | 333-232572 | 10.5 | 07/22/19 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 | [Opinion of Cooley LLP](d475628dex51.htm) |  |  |  |  | X |
| &nbsp;&nbsp;&nbsp;&nbsp;23.1 | [Consent of Independent Registered Public Accounting Firm](d475628dex231.htm) |  |  |  |  | X |
| &nbsp;&nbsp;&nbsp;&nbsp;23.2 | [Consent of Cooley LLP. Reference is made to Exhibit 5.1 to this Registration Statement](d475628dex51.htm) |  |  |  |  | X |
| &nbsp;&nbsp;&nbsp;&nbsp;24.1 | [Power of Attorney. Reference is made to the signature page of this Registration Statement](#tx475628_a) |  |  |  |  | X |
| 107 | [Filing Fee Table.](d475628dexfilingfees.htm) |  |  |  |  | X |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California on March 14, 2023.

---

| | |
|:---|:---|
| **RAPT THERAPEUTICS, INC.** | **RAPT THERAPEUTICS, INC.** |
| By: | /s/ Brian Wong, M.D., Ph.D. |
|  | Brian Wong, M.D., Ph.D. |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY** 

**KNOW ALL PERSONS BY THESE PRESENTS,** that each person whose signature appears below constitutes and appoints Brian Wong and Rodney Young, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their, his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Brian Wong, M.D., Ph.D.<br> Brian Wong, M.D., Ph.D. | President, Chief Executive Officer and Director<br> *(principal executive officer)* | March 14, 2023 |
| /s/ Rodney Young<br> Rodney Young | Chief Financial Officer and Secretary<br> *(principal financial officer and principal accounting officer)* | March 14, 2023 |
| /s/ William Rieflin<br> William Rieflin | Chair of the Board of Directors | March 14, 2023 |
| /s/ Michael F. Giordano, M.D.<br> Michael F. Giordano, M.D. | Director | March 14, 2023 |
| /s/ Lori Lyons-Williams<br> Lori Lyons-Williams | Director | March 14, 2023 |
| /s/ Mary Ann Gray, Ph.D.<br> Mary Ann Gray, Ph.D. | Director | March 14, 2023 |
| /s/ Linda Kozick<br> Linda Kozick | Director | March 14, 2023 |
| /s/ Wendye Robbins, M.D.<br> Wendye Robbins, M.D. | Director | March 14, 2023 |

---

## Exhibit 5.1

**EXHIBIT 5.1**![LOGO](g475628g50m98.jpg)

Michael Tenta

+1 650 843 5636

mtenta@cooley.com

March 14, 2023

RAPT Therapeutics, Inc.

561 Eccles Avenue

South San Francisco, CA 94080

**Re: Registration Statement on Form S-8** 

Ladies and Gentlemen:

We have acted as counsel to RAPT Therapeutics, Inc., a Delaware corporation (the "***Company***"), in connection with the filing of a registration statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering of up to 1,370,173 shares (the "***Shares***") of the Company's Common Stock, par value $0.0001 per share ("***Common Stock*** issuable pursuant to the Company's 2019 Equity Incentive Plan (the "***Plan***").

In connection with this opinion, we have examined and relied upon the Registration Statement and related prospectuses, the Plan, the Company's certificate of incorporation and bylaws, each as currently in effect, and originals or copies certified to our satisfaction of such other records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than by the Company where authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan, the Registration Statement and related prospectuses, will be validly issued, fully paid, and nonassessable (except as to Shares issued pursuant to certain deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Sincerely,

**COOLEY LLP** 

---

| | |
|:---|:---|
| By: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Michael Tenta |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Michael Tenta |

---

Cooley LLP 3175 Hanover Street Palo Alto, CA 94304-1130

t: (650) 843-5000 f: (650) 849-7400 cooley.com

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2019 Equity Incentive Plan of RAPT Therapeutics, Inc. of our report dated March 14, 2023, with respect to the consolidated financial statements of RAPT Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Mateo, California

March 14, 2023

## Ex-Filing

**Exhibit 107** 

**Calculation of Filing Fee Tables** 

**<u>Form S-8</u>**

(Form Type)

**<u>RAPT Therapeutics, Inc.</u>**

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u> 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security Type** | **Security**<br> **Class**<br> **Title** | **Fee**<br> **Calculation**<br> **Rule** | **Amount**<br> **Registered (1)** | **Proposed**<br> **Maximum**<br> **Offering<br>Price Per**<br> **Share (2)** | **Maximum**<br> **Aggregate**<br> **Offering**<br> **Price** | **Fee**<br> **Rate** | **Amount of**<br> **Registration**<br> **Fee** |
| &nbsp;&nbsp;&nbsp; Fees to Be<br> Paid | Equity | Common Stock,<br> par value<br>$0.0001 per<br>share | 457(c) and<br>457(h) | 1370173(3) | $29.67 | $40653033 | $110.20<br>per<br>$1,000,000 | $4480 |
| &nbsp;&nbsp;&nbsp; Fees<br> Previously<br> Paid |  |  |  |  |  |  |  |  |
|  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $40653033 |  | $4480 |
|  | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  |  |
|  | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |
|  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $4480 |

---

(1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "  ***Securities Act*** "), this Registration Statement shall also cover any additional shares of the Registrant's Common Stock that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization, or
other similar transaction effected that results in an increase to the number of outstanding shares of Registrant's Common Stock, as applicable.

(2) Estimated in accordance with Rule 457(c) and Rule 457(h) promulgated under the Securities Act solely for the
purpose of calculating the registration fee, on the basis of $29.67 per share, which is the average of the high and low prices of the Registrant's Common Stock, as reported on the Nasdaq Global Market on March 9, 2023.

(3) Consists of 1,370,173 additional shares of Common Stock that were automatically added to the shares reserved
for future issuance in the RAPT Therapeutics, Inc. 2019 Equity Incentive Plan (the "Plan") on January 1, 2023 pursuant to an "evergreen" provision contained in the Plan, which provides that the number of shares available
under the Plan will automatically increase on January 1 of each year, through and including January 1, 2029, in an amount equal to the lesser of (i) 4% of the total number of shares of Capital Stock (as defined in the Plan) outstanding on
December 31 of the preceding calendar year or (ii) such smaller number of shares as the Registrant's Board of Directors may designate prior to the applicable January 1.